Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales

Psychiatry Research

Volumn 209, Issue 3, 2013, Pages 406-411

  Kishimoto, Taishiro ^a,b,c,d   Watanabe, Koichiro ^a,e   Uchida, Hiroyuki ^a,f   Mimura, Masaru ^a   Kane, John M ^b,c,d,g   Correll, Christoph U ^b,c,d,g  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic combination therapy; Attitudes; Concerns; Polypharmacy; Schizophrenia; Survey

Indexed keywords

CHLORPROMAZINE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADVERSE OUTCOME; ANTIPSYCHOTIC POLYPHARMACY; ARTICLE; CONTROLLED STUDY; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HUMAN; JAPAN; JAPANESE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST;

ANTIPSYCHOTIC COMBINATION THERAPY; ATTITUDES; CONCERNS; POLYPHARMACY; SCHIZOPHRENIA; SURVEY;

ANTIPSYCHOTIC AGENTS; ATTITUDE; FEMALE; HEALTH SURVEYS; HUMANS; JAPAN; MALE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PREDICTIVE VALUE OF TESTS; PRESCRIPTION DRUGS; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS, NONPARAMETRIC;

EID: 84885476215     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.03.014     Document Type: Article

References (43)

1. Argo, T.R., Crismon, M.L., Miller, A.L., Moore, T.A., Bendele, S.D., Suehs, B., 2008. Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm. Texas Department of State Health Services, Austin, Texas.
2. Baandrup L., Allerup P., Lublin H., Nordentoft M., Peacock L., Glenthoj B. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients. Acta Psychiatrica Scandinavica 2010, 122:367-374.
3. Baandrup L., Sørensen J., Lublin H., Nordentoft M., Glenthoj B. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. European Journal of Health Economics 2012, 13:355-363.
4. Broekema W.J., de Groot I.W., van Harten P.N. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharmacy World and Science 2007, 29:126-130.
5. Brunot A., Lachaux B., Sontag H., Casadebaig F., Philippe A., Rouillon F., Cléry-Melin P., Hergueta T., Llorca P.M., Moreaudefarges T., Guillon P., Lebrun T. Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002, 28:129-138.
6. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010, 36:71-93.
7. Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia. Canadian Journal of Psychiatry 2005, 50:7S-57S.
8. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 2001, 158:518-526.
9. Chue P., Welch R., Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Canadian Journal of Psychiatry 2001, 46:86-87.
10. Clark R.E., Bartels S.J., Mellman T.A., Peacock W.J. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin 2002, 28:75-84.
11. Correll C.U., Gallego J.A. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatric Clinics of North America 2012, 35(3):661-681.
12. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophrenia Research 2007, 89:91-100.
13. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009, 35:443-457.
14. Correll C.U., Shaikh L., Gallego J.A., Nachbar J., Olshanskiy V., Kishimoto T., Kane J.M. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research 2011, 131:58-62.
15. Essock S.M., Schooler N.R., Stroup T.S., McEvoy J.P., Rojas I., Jackson C., Covell N.H., Network S.T. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 2011, 168:702-708.
16. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J., Guideli W.T.F.T. World Federation of Societies of Biological Psychiatry (WFSBP)-guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005, 6:132-191.
17. Faries D., Ascher-Svanum H., Zhu B., Correll C., Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
18. Fleischhacker, W.W., Uchidam, H. Critical review of antipsychotic polypharmacy in the treatment of schizophreniaInternational Journal of Neuropsychopharmacology, in press. http://dx.doi.org/10.1017/S1461145712000399.
19. Fourrier A., Gasquet I., Allicar M.P., Bouhassira M., Lépine J.P., Bégaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. British Journal of Clinical Pharmacology 2000, 49:80-86.
20. Gallego J.A., Bonetti J., Zhang J., Kane J.M., Correll C.U. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research 2012, 138:18-28.
21. Gallego J.A., Nielsen J., De Hert M., Kane J.M., Correll C.U. Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety 2012, 11:527-542.
22. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 2004, 65:1377-1388.
23. Hazra M., Uchida H., Sproule B., Remington G., Suzuki T., Mamo D.C. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry and Clinical Neurosciences 2011, 65:676-678.
24. Ito C., Kubota Y., Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry and Clinical Neurosciences 1999, 53(Suppl.):S35-40.
25. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British Journal of Psychiatry 2005, 187:243-247.
26. Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and Drug Safety 2003, 12:41-48.
27. Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V. Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 2006, 188:122-127.
28. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
29. Kreyenbuhl J., Valenstein M., McCarthy J.F., Ganoczy D., Blow F.C. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 2006, 84:90-99.
30. Laska E., Siegel C., Simpson G. Automated review system for orders of psychotropic drugs. Archives of General Psychiatry 1980, 37:824-827.
31. McGorry P., Killackey E., Lambert T., Lambert M., Jackson H., Codyre D., James N., Pantelis C., Pirkis J., Jones P., Durie M.A., McGrath J., McGlashan T., Malla A., Farhall J., Hermann H., Hocking B., Royal Australian New Zealand C. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005, 39:1-30.
32. National Collaborating Centre for Mental Health The NICE Guidelines on Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care 2010, The British Psychological Society and The Royal College of Psychiatrists, Leicester, London. update edition.
33. Nielsen J., Dahm M., Lublin H., Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 2010, 24:965-971.
34. Potkin S.G., Thyrum P.T., Alva G., Bera R., Yeh C., Arvanitis L.A. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Journal of Clinical Psychopharmacology 2002, 22:121-130.
35. Procyshyn R.M., Kennedy N.B., Tse G., Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Canadian Journal of Psychiatry 2001, 46:334-339.
36. Sernyak M.J., Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 2004, 65:1597-1600.
37. Sim K., Su A., Chan Y.H., Shinfuku N., Kua E.H., Tan C.H. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry and Clinical Neurosciences 2004, 58:324-329.
38. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry 2004, 11:313-327.
39. Tani H., Uchida H., Suzuki T., Fujii Y., Mimura M. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophrenia Research 2013, 143(1):215-220.
40. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatric Services 2003, 54:55-59.
41. Thompson A., Sullivan S.A., Barley M., Strange S.O., Moore L., Rogers P., Sipos A., Harrison G. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards-a cluster randomized controlled trial. Psychological Medicine 2008, 38:705-715.
42. Wang P.S., West J.C., Tanielian T., Pincus H.A. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophrenia Bulletin 2000, 26:451-457.
43. Yoshio T., Inada T., Uno J., Miwa T., Kitagawa K., Miyahara Y., Umeda K., Kato T., Inagaki A., Nabeshima T. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Human Psychopharmacology 2012, 27:70-75.